Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Assessing patient satisfaction among ABHRS surgeons: Opportunities to improve.

Hakimi AA, Yasmeh JP, Foulad DS.

J Cosmet Dermatol. 2019 May 27. doi: 10.1111/jocd.13001. [Epub ahead of print]

PMID:
31134743
2.

Nanoparticulate mineralized collagen glycosaminoglycan materials directly and indirectly inhibit osteoclastogenesis and osteoclast activation.

Ren X, Zhou Q, Foulad D, Dewey MJ, Bischoff D, Miller TA, Yamaguchi DT, Harley BAC, Lee JC.

J Tissue Eng Regen Med. 2019 May;13(5):823-834. doi: 10.1002/term.2834. Epub 2019 Apr 15.

PMID:
30803152
3.

Differences in surgical outcomes for patients with craniosynostosis in the US: impact of socioeconomic variables and race.

Shweikeh F, Foulad D, Nuño M, Drazin D, Adamo MA.

J Neurosurg Pediatr. 2016 Jan;17(1):27-33. doi: 10.3171/2015.4.PEDS14342. Epub 2015 Sep 25.

PMID:
26407174
4.

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma.

Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A.

Mol Cancer. 2015 Jul 2;14:128. doi: 10.1186/s12943-015-0393-2. No abstract available.

5.

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.

Atefi M, Titz B, Avramis E, Ng C, Wong DJ, Lassen A, Cerniglia M, Escuin-Ordinas H, Foulad D, Comin-Anduix B, Graeber TG, Ribas A.

Mol Cancer. 2015 Feb 3;14:27. doi: 10.1186/s12943-015-0293-5.

6.

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.

Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A.

Mol Cancer. 2014 Aug 20;13:194. doi: 10.1186/1476-4598-13-194. Erratum in: Mol Cancer. 2015;14:128.

7.

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A.

Clin Cancer Res. 2014 Jul 1;20(13):3446-57. doi: 10.1158/1078-0432.CCR-13-2797. Epub 2014 May 8.

8.

Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.

Candolfi M, King GD, Yagiz K, Curtin JF, Mineharu Y, Muhammad AK, Foulad D, Kroeger KM, Barnett N, Josien R, Lowenstein PR, Castro MG.

Neoplasia. 2012 Aug;14(8):757-70.

9.

B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.

Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, Foulad D, Muhammad AK, Salehi S, Keech N, Puntel M, Liu C, Sanderson NR, Kroeger KM, Dunn R, Martins G, Lowenstein PR, Castro MG.

Neoplasia. 2011 Oct;13(10):947-60.

10.

Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.

Candolfi M, Kroeger KM, Xiong W, Liu C, Puntel M, Yagiz K, Muhammad AG, Mineharu Y, Foulad D, Wibowo M, Assi H, Baker GJ, Lowenstein PR, Castro MG.

Anticancer Agents Med Chem. 2011 Oct;11(8):729-38. Review.

11.

Gene therapy and targeted toxins for glioma.

Castro MG, Candolfi M, Kroeger K, King GD, Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad AK, Foulad D, Puntel M, Lowenstein PR.

Curr Gene Ther. 2011 Jun;11(3):155-80. Review.

12.

Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.

Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, Rodriguez R, Lowenstein PR, Castro MG.

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20021-6. doi: 10.1073/pnas.1008261107. Epub 2010 Oct 28.

13.

Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.

Muhammad AK, Puntel M, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Lawrence K, Bondale NS, Lerner J, Baker GJ, Foulad D, Pechnick RN, Palmer D, Ng P, Lowenstein PR, Castro MG.

Clin Pharmacol Ther. 2010 Aug;88(2):204-13. doi: 10.1038/clpt.2009.260. Epub 2010 Feb 17.

14.

Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.

Ghulam Muhammad AK, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y, Kroeger KM, Treuer KA, Nichols WS, Sanderson NS, Yang J, Khayznikov M, Van Rooijen N, Lowenstein PR, Castro MG.

Clin Cancer Res. 2009 Oct 1;15(19):6113-27. doi: 10.1158/1078-0432.CCR-09-1087. Epub 2009 Sep 29.

15.

Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.

Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK, Puntel M, Kroeger KM, Liu C, Lee S, Curtin JF, King GD, Lerner J, Sato K, Mineharu Y, Xiong W, Lowenstein PR, Castro MG.

Clin Cancer Res. 2009 Jul 1;15(13):4401-14. doi: 10.1158/1078-0432.CCR-09-0155.

Supplemental Content

Loading ...
Support Center